Vaccines
[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
20 Aug, 2021 | 10:03h | UTCCommentaries:
Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard
Commentary on Twitter
New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn
— Eric Topol (@EricTopol) August 19, 2021
IDSA response to plan for supplemental vaccine doses for vaccinated individuals.
19 Aug, 2021 | 09:02h | UTC
Studies: COVID vaccine protection waning against infection but not hospitalization.
19 Aug, 2021 | 09:05h | UTCStudies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP
Commentary on Twitter (thread – click for more)
Very excited to share our most recent publication about #CovidVaccine effectiveness, just published today by the IVY network. Especially relevant in light of today’s news about #boosters (spoiler – I’m skeptical about the need for boosters for all). ?https://t.co/GbAxgzpo7R
— Nida Qadir, MD (@NidaQadirMD) August 18, 2021
U.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists.
19 Aug, 2021 | 09:00h | UTCU.S. officials’ decision on Covid-19 booster shots baffles — and upsets — some scientists – STAT
Commentary on Twitter
Scientists I spoke to today had a lot of questions about the administration's decision to start giving Americans 3rd doses of the mRNA vaccines next month. “I’m not sure we had enough [data] to pull the trigger right now," one said. https://t.co/eHUndOrQL4
— Helen Branswell (@HelenBranswell) August 18, 2021
Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.
18 Aug, 2021 | 09:04h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter (thread – click for more)
Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ— Eric Topol (@EricTopol) August 17, 2021
Editorial: COVID-19 vaccine equity and booster doses – “by Aug 9, only 12·6 million of the 4·46 billion doses administered globally were in low-income countries”.
18 Aug, 2021 | 08:58h | UTCCOVID-19 vaccine equity and booster doses – The Lancet Infectious Diseases
See also: New waves, new variants, old inequity: a continuing COVID-19 crisis – BMJ Global Health
Editorial: The WHO is right to call a temporary halt to COVID vaccine boosters.
18 Aug, 2021 | 08:56h | UTCThe WHO is right to call a temporary halt to COVID vaccine boosters – Nature
Opinion | Go Ahead. Vaccinate the Kids. The risk of vaccinating children will never be zero, but the alternative is so much worse.
18 Aug, 2021 | 08:50h | UTCGo Ahead. Vaccinate the Kids. – The Atlantic
[Preprint] Full vaccination suppresses SARS-CoV-2 delta variant mutation frequency.
17 Aug, 2021 | 08:59h | UTCFull vaccination suppresses SARS-CoV-2 delta variant mutation frequency – medRxiv
Commentary: Research debunks myth that COVID vaccination promotes mutations – News Medical
Commentary on Twitter
Evidence that vaccinations successfully suppress viral mutations and that the unvaccinated are the source of the variants. https://t.co/U80T4JLO7A
"No one is safe until everyone is safe." pic.twitter.com/B2pVeMm96r— Daniel Griffin MD PhD (@DanielGriffinMD) August 15, 2021
FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.
16 Aug, 2021 | 01:22h | UTCCommentaries:
CDC, FDA recommend COVID booster for immune-compromised – CIDRAP
FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT
Covid booster: US approves third jab for the immunocompromised – BBC
CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR
6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR
CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN
Commentary on Twitter
The Infectious Diseases Society of America (IDSA) supports the @FDA and @CDCgov's decision to authorize a supplemental vaccine dose for immunocompromised patients.
Read our statement: https://t.co/odzzSgIxnY pic.twitter.com/4PZfUwpjhM
— IDSA (@IDSAInfo) August 13, 2021
Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told.
16 Aug, 2021 | 01:17h | UTCDon’t Panic, But Breakthrough Cases May Be a Bigger Problem Than You’ve Been Told – Intelligencer
Commentary on Twitter (thread – click for more)
The vaccines are still performing quite well in preventing severe disease. But with Delta they are doing much worse in stopping transmission. Breakthroughs are probably now 10-20% of new infections, and perhaps as much as 5% of new deaths. A thread. (1/x) https://t.co/NvGends1ZP
— David Wallace-Wells (@dwallacewells) August 12, 2021
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
16 Aug, 2021 | 01:19h | UTCCOVID-19 Vaccines While Pregnant or Breastfeeding – Centers for Disease Control and Prevention
Related:
Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.
Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to antibody responses in SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine.
16 Aug, 2021 | 01:15h | UTCCommentary (on the preprint): Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study – News Medical
Related: More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID. (studies on the subject)
Study suggests a potential protective benefit from MMR and TDP vaccines in reducing the risk of severe Covid-19 infections.
16 Aug, 2021 | 01:04h | UTC
Commentary on Twitter
New @MedCellPress
Prior Measles-Mumps-Rubella (MMR) or Tetanus-Diptheria-Pertussis (Tdap) vaccination induces a T-cell response that overlaps with #SARSCoV2 and appears to offer some (~20-30%) protection from severe Covid-19https://t.co/fYT7Qole8s pic.twitter.com/hMkHXvNQYU— Eric Topol (@EricTopol) August 14, 2021
Opinion: Making vaccines available to other countries before offering domestic booster vaccinations.
13 Aug, 2021 | 09:48h | UTCMaking Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA
Opinion: Time for a smart approach to boosters.
13 Aug, 2021 | 09:51h | UTCTime for a Smart Approach to Boosters – Think Global Health
Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.
13 Aug, 2021 | 09:47h | UTC
Commentary on Twitter
Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease https://t.co/BXkUQGMmbO via @JAMAOnc part of @JAMANetwork
— Tom Ollila (@OllilaTom) August 11, 2021
RCT: Evaluation of Moderna mRNA vaccine in adolescents.
12 Aug, 2021 | 09:58h | UTCEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine
Related:
Commentaries on Twitter
The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29
— NEJM (@NEJM) August 11, 2021
The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx
— Eric Topol (@EricTopol) August 11, 2021
[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.
12 Aug, 2021 | 09:53h | UTCRelated:
Commentary on Twitter
New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH— Eric Topol (@EricTopol) August 11, 2021
Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.
12 Aug, 2021 | 08:59h | UTCFrequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA
Vaccination: Effectiveness versus Efficacy.
12 Aug, 2021 | 09:01h | UTCVaccination: Effectiveness versus Efficacy – by Luis Correa, MD
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
12 Aug, 2021 | 09:05h | UTCCommentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Related:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
Vaccines given in last 20 years could prevent 50 million deaths in LMICs.
12 Aug, 2021 | 08:43h | UTCVaccines given in last 20 years could prevent 50 million deaths in LMICs – Imperial College London
Original study: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world – eLife
CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.
11 Aug, 2021 | 08:45h | UTC
Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.
11 Aug, 2021 | 08:44h | UTCRelated:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
Big day! Our paper is now published in JAMA Cardiology! @JAMA_current @JAMACardio @JAMANetwork
COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia with Cerebral Venous Sinus Thrombosis
Full-text: https://t.co/XoY0xoztXT pic.twitter.com/IfAmsxomPy
— John G. Rizk (@JohnGRizk) August 10, 2021